Company logo

CYTO - Altamira Therapeutics Ltd.

NASDAQ -> Healthcare -> Biotechnology
Hamilton, Bermuda
Type: Equity

CYTO price evolution
CYTO
(in millions $) 31 Jan 2024 30 Jul 2023 31 Jan 2023 30 Jul 2022
Current assets
Cash
Short term investments
Net receivables $0.07 $0.79 $0.76 $0.63
Inventory $0.27 $0.01 $0.15
Total current assets $1.22 $1.73 $1.77 $1.93
Long term investments
Property, plant & equipment $0.08 $0.39 $0.45 $0.51
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $7.69 $6.2 $6.3 $18.48
Current liabilities
Accounts payable $0.44 $1.96 $4.91 $3.16
Deferred revenue
Short long term debt
Total current liabilities $0.89 $5.37 $12.88 $9.79
Long term debt $0.93
Total noncurrent liabilities
Total debt
Total liabilities $1.24 $8.03 $14.62 $10.8
Shareholders' equity
Retained earnings -$18.05 -$19.85 -$201.43 -$182.6
Other shareholder equity $4.4 $0.87 $0.26 -$0
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 30 Jan 2021
Current assets
Cash $0.62 $0.02 $0.98 $12.01
Short term investments
Net receivables $0.07 $0.76 $0.94 $0.09
Inventory $0.01 $0.84 $0
Total current assets $1.22 $1.77 $3.76 $12.39
Long term investments
Property, plant & equipment $0.08 $0.45 $0.56 $0.05
Goodwill & intangible assets
Total noncurrent assets $9.79
Total investments
Total assets $7.69 $6.3 $18.84 $22.18
Current liabilities
Accounts payable $0.41 $4.77 $3.54 $0.81
Deferred revenue
Short long term debt
Total current liabilities $0.89 $12.88 $4.86 $3.23
Long term debt
Total noncurrent liabilities $1.07
Total debt
Total liabilities $1.24 $14.62 $6.13 $4.3
Shareholders' equity
Retained earnings -$18.05 -$201.43 -$176.02 -$171.33
Other shareholder equity $4.4 $0.26 $0.06 $0.07
Total shareholder equity
(in millions $) 31 Jan 2022 29 Jul 2021 31 Jan 2021 29 Jul 2020
Revenue
Total revenue $0.06
Cost of revenue
Gross Profit -$2.18
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $8.47 $2.86
Operating income
Income from continuing operations
EBIT
Income tax expense $0.03 -$0.01
Interest expense $0.04 -$2.69
Net income
Net income -$10.64 -$5.54
Income (for common shares)
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Revenue
Total revenue $0.06
Cost of revenue
Gross Profit -$2.18
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $13.39 $5.63 $7.31 $10.95
Operating income -$5.63 -$7.31
Income from continuing operations
EBIT
Income tax expense $0.02 -$0.02 -$0.2 $0.16
Interest expense -$0.27 $0.14 $0.03 $0.14
Net income
Net income -$17.39 -$8.75 -$6.67 -$11.5
Income (for common shares)
(in millions $) 31 Jan 2022 30 Jul 2021 31 Jan 2021 29 Jul 2020
Net income -$7.41 -$2.76
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$5.4 -$1.69
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$3.51 -$2.18 -$2.31 -$0.79
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $6.61 $4.22 $16.96 $1.08
Effect of exchange rate $0.29 $0.3 $0.07 $0
Change in cash and equivalents -$10.28 -$3.06 $9.88 -$1.4
(in millions $) 31 Jan 2022 30 Jan 2021 30 Jan 2020 31 Jan 2019
Net income -$8.75 -$6.67
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$5.17 -$8.45
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$3.51 -$2.47 -$3.02 -$1.82
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $6.61 $18.09 $7.43 $5.73
Effect of exchange rate $0.29 $0.08 $0.01 -$0.26
Change in cash and equivalents -$10.28 $10.53 -$4.03 -$9.58
Fundamentals
Market cap $1.79M
Enterprise value N/A
Shares outstanding 1.48M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 1.38
Quick ratio N/A